Connect with us

NEWS

Giorgino Puts the Liver on Europe’s Diabetes Checklist

EASD president Francesco Giorgino used Milan 2026 to rank MASLD with heart and kidney disease and to push intensive treatment of recent-onset type 2 diabetes.

Published

on

Francesco Giorgino used his first EASD meeting as president to put the liver on the same checklist as the heart. The 62nd EASD Annual Meeting ran from 28 September to 2 October 2026 at Allianz MiCo in Milan, drawing more than 16,000 people.

The science on GLP-1 drugs and SGLT2 inhibitors was already familiar. What he pressed, in the opening address and in a later interview, was a care gap: people with recent-onset type 2 diabetes in Europe still wait too long for the medicines the new joint guidance says should start early, and metabolic liver disease is still treated as someone else’s problem.

He Wants the First Months After Diagnosis to Count

Giorgino, professor of endocrinology at the University of Bari Aldo Moro and head of endocrinology at University Hospital Policlinico Consorziale, had been senior vice president for three years before the Milan meeting. The Bari announcement of his election went out on 18 September 2025. He will lead the association, founded in 1965 and now counting over 20,000 members in more than 130 countries, through 2028.

“First of all, I would say that we are working in continuity,” he said. The project, built with the previous board, is to make EASD the reference society for diabetes worldwide, including regions outside Europe that carry a heavy share of the disease. That is the public slogan. The operational bet is narrower.

He wants EASD to run its own research, not only fund other people’s. The first topic is recent-onset type 2 diabetes, with a possible later extension to pre-diabetes. The aim is to map how the condition is diagnosed and treated in Europe, catch autoimmune diabetes that has been labelled type 2 because nobody tested for autoantibodies, and push past the habit of delaying the strongest drugs.

“This research also aims to show that T2D could even be reversed if it is detected early and treated intensively,” he said. He pointed to new medicines, bariatric surgery, and marked dietary restriction as routes that have already shown it can be done. “I think it is time to change the paradigm of management and be more intensive early on.”

European clinic records already hint at how uncommon a clean remission still is once GLP-1 drugs are started late. In a multicentre Italian study of 14,141 adults who began a GLP-1 receptor agonist, remission rates ran from 5.8% under the strictest definition to 18.3% under the loosest, over a mean four years of follow-up. Most of those people had already lived with diabetes for about a decade. Giorgino’s project is aimed at the opposite end of that timeline.

The Liver Joins the Heart on the Checklist

Cardiorenal protection from GLP-1-based therapies and SGLT2 inhibitors is, in his words, well established and still unevenly used. The session traffic in Milan, and the document presented on the closing Friday, put a fourth organ on that list.

The message, essentially, is that we need to look at the liver as closely as we look at the heart, the blood vessels, and the kidneys.

Francesco Giorgino, President, European Association for the Study of Diabetes

He was describing the 2026 ADA-EASD consensus report on type 2 diabetes, published on 2 October 2026 in Diabetologia and Diabetes Care. Giorgino sat on the 16-member writing group. The report ranks metabolic dysfunction-associated steatotic liver disease, including steatohepatitis, with atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease as conditions every person with type 2 diabetes should have assessed.

That ranking is a workload change, not a slogan. Clinical diabetologists, he said, now need to know how to screen for liver disease and how to watch it. EASD is doing that work with the European Association for the Study of the Liver. On 28 September 2026, EASL, EASD, and the European Association for the Study of Obesity posted joint guidance in the Journal of Hepatology on when to use resmetirom or semaglutide as MASH-targeted therapy.

FOUR ORGANS ON THE 2026 CHECKLIST

ConditionWhat clinics are asked to doTherapies already in reach
Atherosclerotic cardiovascular diseaseAssess in every person with type 2 diabetesGLP-1-based therapy for major heart events; add an SGLT2 inhibitor when both are indicated
Heart failureAssess in every person with type 2 diabetesSGLT2 inhibitors as the base; GLP-1-based therapy when weight or atherosclerosis is also in play
Chronic kidney diseaseAssess in every person with type 2 diabetesSGLT2 inhibitors, with GLP-1-based therapy added for extra kidney and weight benefit
MASLD and MASHAssess as closely as the other threeGLP-1-based therapy when obesity or type 2 diabetes is present; resmetirom for noncirrhotic F2 to F3 disease

Resmetirom, sold as Rezdiffra, received conditional EU approval of resmetirom on 18 August 2025 for adults with noncirrhotic MASH and fibrosis stages F2 to F3, used with diet and exercise. The liver-diabetes-obesity guidance says semaglutide may be preferred when obesity, type 2 diabetes, cardiovascular disease, or chronic kidney disease is present, and resmetirom may come first in people without obesity or who cannot take a GLP-1 drug. Neither is advised as MASH-targeted treatment in cirrhosis until stronger liver-outcome data arrive.

What the 2026 ADA-EASD Consensus Changed

The last joint update was in 2022. The 2026 text, co-chaired by Melanie Davies for EASD and John Buse for the ADA, widens the job from glucose control to long-term conditions that travel with type 2 diabetes. Its closing line is an implementation warning: outcomes can change if clinics actually use the tools they already have.

SHIFTS IN THE 2026 JOINT REPORT

  • From diagnosis: SGLT2 inhibitors and GLP-1-based therapies, including tirzepatide, are advocated earlier, potentially from diagnosis, for organ protection, not only after metformin has failed.
  • Early combinations: Using both classes sooner is to be considered when cardiovascular disease, chronic kidney disease, or heart failure is already present.
  • Weight beside glucose: Weight-loss targets are treated as essential, with weight-lowering drugs preferred and metabolic surgery kept in view.
  • The liver on the list: MASLD and MASH join heart, vessel, and kidney disease as conditions to assess in every adult with type 2 diabetes.
  • A wider screen: Sleep apnoea, cognition, and mental health are pulled into treatment choices, and alternative diagnoses such as type 1, monogenic diabetes, and hypercortisolism are to be reconsidered at diagnosis and later if the response is odd.

Davies and Buse presented the final report in Milan on 2 October 2026. A draft had already gone out for public comment at the ADA meeting in New Orleans earlier in 2026. Metformin is no longer framed as a mandatory first step before organ-protective drugs can be started.

SGLT2 and GLP-1 From the First Visit

Giorgino tied that line directly to European practice. People with a new type 2 diagnosis, he said, are not getting the best management now available, “especially given the new medications.” The consensus says those medicines should come in very early. His research project is designed to show where identification fails, where labels are wrong, and where clinics stall.

Dual agonists that add glucagon activity, he added, are the next wave to watch for metabolic liver disease. That pipeline sits on top of GLP-1 receptor agonists and resmetirom, which already have tools “that have been shown to potentially reduce the burden of the disease.”

Weight Targets Now Match Glucose Targets

The writing group also treats 10% to 15% weight loss as a chance to modify the disease, not only to shrink a number on the scale. That is the same physiology Giorgino invoked when he talked about reversal: get in while the clock is still short, treat hard, and do not wait for a later “step” that the evidence no longer supports.

Teplizumab Has a Licence but Few Infusion Chairs

Type 1 diabetes had its own thread in Milan, and it followed the same pattern: a disease-modifying drug exists, Europe has authorised it, and clinics still cannot offer it as routine care. Giorgino pointed to the staging work of Anette-Gabriele Ziegler at Helmholtz Munich, who delivered the 58th Claude Bernard Lecture. Autoantibodies, she has shown, mark the path from no disease to full disease, cut the risk of ketoacidosis at diagnosis, and open a window for therapy that changes the course.

Teplizumab is the first such therapy. In the United States it has been on the market for years. The European Commission granted EU authorisation for teplizumab, branded Teizeild, on 8 January 2026, to delay stage 3 type 1 diabetes in people aged 8 years and older with stage 2 disease. Sanofi Winthrop Industrie holds the licence. At the Milan meeting, eight months later, Giorgino still described it as “not yet fully available in Europe.”

THE ACCESS CLOCK FOR TEPLIZUMAB AND RESMETIROM

  1. 18 August 2025: Rezdiffra receives a conditional EU marketing authorisation for noncirrhotic MASH with F2 to F3 fibrosis.
  2. 8 January 2026: Teizeild receives an EU marketing authorisation to delay stage 3 type 1 diabetes in stage 2 disease from age 8.
  3. 28 September 2026: EASD opens in Milan; EASL, EASD, and EASO post MASH treatment guidance the same week.
  4. 2 October 2026: The ADA-EASD type 2 diabetes consensus is presented and published as the meeting closes.

The EMA’s main study enrolled 76 adults and children. After one 14-day course, average time to stage 3 was around 50 months with Teizeild and around 25 months with placebo. The drug is given as a vein infusion lasting at least 30 minutes, once a day for 14 consecutive days, in a facility that can treat cytokine release syndrome. That reaction may affect up to 1 in 100 people. Common effects, in more than 1 in 10, include low lymphocytes, low white cells, low neutrophils, and rash.

Antonio Pérez Pérez, former president of the Spanish Diabetes Foundation, said in November 2026 that Spain’s health ministry had still to clear hospital use and that local protocols would be needed because the drug is intravenous and hospital-only. The lag is the T1D version of the T2D inertia Giorgino wants to measure: a licence is not a clinic slot.

He also said he hoped other disease-modifying candidates would match teplizumab. Until they do, the practical limit is screening. Without autoantibody testing, there is no stage 2 list to infuse.

EASD Starts Mapping How Europe Treats New Type 2

The recent-onset type 2 project is the piece of the presidency that does not fit a congress news cycle. Giorgino wants evidence strong enough to shift policy, including how diabetes is seen at EU level. He was appointed to Italy’s Consiglio Superiore di Sanità in 2025, which puts him closer to that conversation than a typical society president.

WHAT WE KNOW

  • The target: People with a recent type 2 diagnosis in Europe, with pre-diabetes named as a possible later extension.
  • The jobs: Map diagnosis and treatment, find misclassification, and reduce delay in using effective drugs.
  • The claim to test: Intensive early treatment, already shown in trials of diet, surgery, and new medicines, can reverse type 2 diabetes if it is caught soon enough.

WHAT IS UNCONFIRMED

  • The protocol: Sites, sample size, funding, and start date have not been published.
  • The policy path: Whether EU-level attention follows the data is a hope, not a timetable.
  • The reversal rate: No EASD field study has yet shown how often European clinics can reproduce trial remissions in the first months after diagnosis.

Precision medicine is the method he wants underneath that map. He is watching phenotypes by age at onset and by trajectory, especially early-onset type 2 diabetes, because those patients live longer inside an adverse metabolic setting. AI, he said, can rank progressors versus non-progressors from mixed biological, clinical, social, and environmental data, and can already grade retinopathy from retinal vessels. The same platforms would serve the new research project.

A Global Council Built to Spread the Same Playbook

EASD created its Global Council in 2024. Members from regions outside Europe are meant to carry grant calls, travel fellowships, and free e-learning outward, and to bring local problems back in. Giorgino called it a two-way exchange. In his presidential address he flagged a council paper on how to build a diabetes registry: essential modules, how to run it, and how to upgrade it so the same data serve care and research.

He said further documents for a broad audience are already in motion. The European Foundation for the Study of Diabetes, the association’s funding arm, has distributed over 150 million euros in research support. Money is not the gap he keeps naming. Spread is. “This is called implementation science, and we are making an effort in that direction. We are also still learning how to do this, as the EASD has not traditionally been used to these types of processes.”

The opening of the Milan meeting was posted by the society as he spoke.

Teaching accounts spent the weeks after the congress walking generalists through the organ-first shift, which is a fair read of what actually changed. MASLD sessions were not a specialty side hall. They were the point at which a diabetes meeting started treating the liver as routine work. Remote delegates, meanwhile, hit a virtual platform that at times would not load the live programme, a small reminder that even a hybrid congress of more than 16,000 people can fail at the last mile.

Planning for Budapest is already under way. The 63rd Annual Meeting is set for 21 to 24 September 2027; Copenhagen follows on 18 to 22 September 2028. Giorgino would not name 2027 themes before Milan had finished. What he will take there is the same unfinished job he named for the rest of his term: more research generated inside EASD, wider education, a louder file in Brussels, and a shorter distance between a published consensus and a first prescription.

Frequently Asked Questions

Who Is Francesco Giorgino, the EASD President?

He trained in medicine and endocrinology in Italy, completed a doctorate in Naples, and worked from 1990 to 1994 at the Joslin Diabetes Center and Harvard Medical School. He has held the endocrinology chair in Bari since 2002, led the Italian Society of Endocrinology from 2019 to 2021, and, by his university’s 2025 count, had about 300 papers, more than 22,000 citations, and an H-index of 78.

When and Where Was EASD 2026 Held?

It was a hybrid congress at Allianz MiCo, Piazzale Carlo Magno 1, Milan, from 28 September to 2 October 2026, with on-site sessions live-streamed in CEST. Session recordings stayed behind the registration wall until 30 October 2026; the society later opened the media centre, including presentations and e-posters, at no charge.

What Did the 2026 ADA-EASD Type 2 Diabetes Consensus Change?

A 16-member panel, co-chaired by Melanie Davies and John Buse, reviewed trials, reviews, and meta-analyses published in English from 1 May 2022 to 31 December 2025, then wrote to ACCORD consensus rules. The group met online from April 2025 to June 2026 and for two days in person in February 2026, and it treats 10% to 15% weight loss as a disease-modifying target, not only a cosmetic one.

What Is Teizeild Approved for in the European Union?

Teizeild (teplizumab) is authorised to delay stage 3 type 1 diabetes in adults and children aged 8 years and older who already have stage 2 disease, meaning abnormal glucose with no need yet for routine insulin. It is a 14-day intravenous course given in a unit that can treat cytokine release syndrome, and Sanofi has said it is not, for now, seeking an EU licence for people who already have stage 3 disease.

When Is the Next EASD Annual Meeting?

The 63rd Annual Meeting is scheduled for 21 to 24 September 2027 in Budapest, and the 64th for 18 to 22 September 2028 in Copenhagen. Giorgino said the 2027 scientific committee was already working during Milan, but he declined to lock themes until 2026 sessions had been reviewed.

Disclaimer: This article is news reporting and analysis of a scientific meeting, a published consensus, and regulator documents. It is informational only and is not medical advice, a treatment recommendation, or a substitute for clinical judgement. It does not tell any reader to start, stop, or switch a diabetes medicine, a liver drug, an infusion, a diet, or a screening test. Anyone considering a change in care should speak first with a qualified physician or diabetes specialist who knows their history. Figures, licences, and access notes reflect the cited sources on the dates named in the piece and can change as regulators, payers, and clinics update their rules.

Harry is the editor of NEWS ANALYSIS. He writes across the publication's ten desks, with most of his time going to the stories where a number, a filing or a study decides the argument. His working rule is simple: read the source document before writing about it, and tell the reader plainly which parts are established and which are somebody's claim. He is responsible for the standards set out on this site's Editorial Standards and Fact Checking pages, and for correcting the record openly when the publication gets something wrong.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending